Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.7K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prophylactic half-dose platelet transfusion effect on thrombocytopenia, transfusion, and bleeding occurrence in patients with hematologic disease.

American journal of clinical pathology·2026
Same author

Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors.

Journal of clinical apheresis·2025
Same author

Differences in outcomes associated with ABO blood groups in recipients of IVIG.

Blood vessels, thrombosis & hemostasis·2025
Same author

Four-Factor Prothrombin Complex Concentrate vs Plasma in Patients on Vitamin K Antagonists With Gastrointestinal Bleeding or Needing a Gastrointestinal Procedure: A Retrospective Analysis of 2 Randomized Controlled Trials.

Journal of the American College of Emergency Physicians open·2025
Same author

Eliminating leukocyte reduction for whole blood: Is it premature to consider this paradigm-changing practice?

Transfusion·2024
Same author

The Impact of HLA-DQαβ Heterodimer Mismatch on Living Donor Kidney Allograft Outcomes.

Transplantation·2024

Related Experiment Video

Updated: Dec 28, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.2K

HLA-Mediated Platelet Refractoriness.

Amy E Schmidt1, Majed A Refaai1, Myra Coppage1

  • 1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY.

American Journal of Clinical Pathology
|October 5, 2018
PubMed
Summary
This summary is machine-generated.

Human leukocyte antigen (HLA)-mediated platelet refractoriness presents complex challenges. Accurate HLA antibody testing and patient factors guide the selection of appropriate platelet products for successful transfusions.

Keywords:
Complement-dependent cytotoxicity testHLAHLA antibodyPlatelet refractory

More Related Videos

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.1K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K

Related Experiment Videos

Last Updated: Dec 28, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.2K
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.1K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K

Area of Science:

  • Immunology
  • Transfusion Medicine

Background:

  • Platelet refractoriness, particularly that mediated by human leukocyte antigen (HLA) antibodies, poses a significant clinical challenge.
  • Understanding the complexities of HLA antibody detection and associated testing limitations is crucial for effective patient management.

Observation:

  • This review presents a case scenario and literature analysis of platelet refractoriness.
  • Discussion focuses on the methodologies and limitations of human leukocyte antigen (HLA) antibody testing.

Findings:

  • Diagnosis of HLA-mediated refractoriness necessitates careful consideration of patient-specific factors.
  • Panel reactive antibodies (PRA) percentage, HLA typing, and testing limitations inform the selection of optimal platelet products.

Implications:

  • Platelet transfusion strategies, including HLA-matched, antigen-restricted, or cross-matched products, are determined by HLA antibody testing results.
  • Post-transfusion increment counts are monitored to confirm the success of platelet transfusions in refractory patients.